A HER2-positive status reflects breast cancer cells with extra copies of the HER2 gene, or higher expression of HER2 proteins ...
An investigation published in The BMJ raises new concerns over the landmark clinical trial (PLATO) that was used to gain ...
The Institute for Clinical and Economic Review has identified five drugs — Biktarvy, Darzalex, Entresto, Cabometyx, and ...
A Maryland federal court granted summary judgment to AstraZeneca on the claims of a Black female project manager that she faced discrimination due to her race and gender, and retaliation for ...
The benefit of the PARP inhibitor in patients with germline BRCA pathogenic variants remains evident 10 years after the first ...
In a report released today, Steve Scala from TD Cowen maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target of ...
11h
NEW YORK, NY / ACCESSWIRE / December 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ...
An investigation published by The BMJ today raises new concerns over the landmark clinical trial (PLATO) that was used to gain worldwide approval for the anti-platelet drug ticagrelor (Brilinta in the ...
UBS has recently raised AstraZeneca plc (AZN) stock to Neutral rating, as announced on November 20, 2024, according to Finviz. Earlier, on November 6, 2024, Deutsche Bank had raised the stock from a ...
Imlunestrant by itself benefited those with ESR1 mutations but also had broad efficacy in ER-positive HER2-negative tumors when combined with a CDK4/6 inhibitor.
Even when diagnosed early, triple-negative breast cancer (TNBC) has a higher mortality rate compared with other breast cancer ...
AstraZeneca and Merck report Lynparza's significant survival benefits in high-risk breast cancer and Keytruda combo results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback